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Abstract: We performed a serological evaluation of herpes simplex virus (HSV) infections at the time of labor. In order to determine
the seroprevalence of asymptomatic HSV infections in pregnant women, blood samples were collected for antibody measurement
from 130 randomly selected pregnant women. Presence of HSV IgG and IgM antibodies in the serum samples was tested by ELISA.
The prevalence of HSV-1 gG1 antibodies was 90% (117/130), that of HSV-2 gG2 antibodies was 63.1% (82/130) and that of HSV2 IgM antibodies was 13.8% (18/130). Eight (44.4%) of the pregnant women with HSV-2 IgM were at the same time found to
have HSV-2 IgG antibodies, and 10 (55.6%) women were determined to have HSV-2 IgM antibodies. Furthermore, 6 (4.6%) out
of the 130 pregnant women were seronegative for HSV.
In conclusion, the results of our study show that the prevalence of HSV-2 infection (63.1%) is relatively high among asymptomatic
pregnant women in Adana, Turkey. Therefore, to take precautions for reducing the risk of neonatal herpes, the investigation of
HSV-2 type specific antibodies in pregnant women should be offered by using HSV-2 gG2 type specific serological tests that allow
the identification of women with asymptomatic or subclinical genital HSV-2 infection and women susceptible to primary genital HSV2 infection.
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Introduction
The incidence of herpes simplex virus (HSV) infection
has been increasing steadily in recent decades, and
concerns about perinatal HSV infection are growing
among women of reproductive age because of the risk of
transmission of the virus to their babies during
pregnancy, with potentially devastating consequences to
the fetus (1-3).
Genital HSV infection in pregnant women is of
particular importance because of the risk to the fetus and
newborn. Data from several prospective trials have
shown that the major risk to the fetus results from
primary maternal genital HSV infection. Over 95% of
infected babies are born to women who are unaware that
they have genital herpes. The most severe forms of
neonatal disease occur when infection of the mother
occurs during the last stage of pregnancy, at a time when
maternal antibodies develop much more slowly for

passive transfer of the protective antibodies to the fetus
(1,3-5).
The most severely affected population is neonates,
who acquire HSV infection after exposure to the virus
during birth (5). This is a relatively rare infection,
occurring in about 1 in 3,000 births in the northwestern
United States and with a somewhat lower frequency in
other areas. However, these infections result in
permanent neurological damage for many infants despite
appropriate antiviral therapy. The increasing acquisition
rate of genital herpes among women of childbearing age
suggests that more neonates may be exposed to the virus
than in past decades (3,5).
Previous studies have suggested that genital HSV
infection acquired during pregnancy is associated with
preterm labor, intrauterine growth retardation, and
spontaneous abortion (1,5).
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The best method for detecting HSV infections in the
general population is measuring type-specific serum
antibodies (6).
In this study, we used serological methods to
investigate the seroprevalence of HSV infection among
pregnant women.

The average absorbance (OD) value of the cutoff
serum run in duplicate was calculated. Then the cutoff
index (COI) of each serum sample was determined by
dividing the OD obtained for that serum sample by the
average OD of the cutoff serum. A COI below or equal to
1 was considered negative, a COI above 1.1 was
considered positive, and a COI between 1 and 1.1 was
considered borderline.

Materials and Methods

ELISA procedure
Determination of HSV-2 IgG Antibodies: The
reactions were carried out on polystyrene plates (Costar,
USA). One hundred mililiters of antigen diluted in sodium
bicarbonate-carbonated 0.05M buffer pH 9.6 was added
to each well. After incubation for 18 h at 4 °C, the excess
antigen was removed by 3 washes with PBS Tween 80 at
0.05%. The blocking step was carried out using 100 µl
of PBS bovine serum albumin 5%, pH 7.6, over 1 h at 37
°C. After washing, the plate was incubated at 37 °C for
60 min, with 100 µl of each serum sample diluted in PBS
Tween (1:100). Unbound antibodies were removed by
washing the plates as described above. One hundred
microliters of monoclonal anti-human IgG Conjugate
(Sigma), diluted in PBS-Tween, was added to each well
and the plates were incubated for 60 min and washed.
The anti-human IgG conjugate (Sigma) was used at a
dilution of 1:10,000. The plate was washed after
incubation for 1 h at 37 °C, and 100 µl of
orthophenylene-diamine (OPD) substrate solution was
added. The reaction was interrupted using sulfuric acid
1N (50 µl per well). Absorbances were read using a
microplate reader (Sigma) with a 450 nm filter.
The determination of HSV-2 IgM, HSV-1 IgG and
HSV-1 IgM antibodies was carried out as for the
determination of HSV-2 IgG antibodies. The anti-human
IgM conjugate (Sigma, USA) was used at a dilution of
1:10,000 and the results were evaluated as above.
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Results
In this study the pregnant women were aged between
17 and 44 (26.7 ± 5.6). Considering the age distribution,
21 of the pregnant women were 17-20 years old, 37
were 21-25 years old, 40 were 26-30 years old and 32
were above 30 years old.
All pregnant women without an apparent history of
genital herpes enrolled in the study. It was found that the
prevalence of HSV-2 IgG was 63.1% (82/130), and the
prevalence of HSV-1 IgG was 90% (117/130). In
addition, 13.8% (18/130) of the pregnant women had
HSV-2 IgM antibodies. Eight (44.4%) of the pregnant
women with HSV-2 IgM were at the same time found to
have HSV-2 IgG antibodies, and 10 (55.6%) women
were determined to have HSV-2 IgM antibodies.
Furthermore, 6 (4.6%) out of the 130 pregnant women
were seronegative for HSV.
Evaluation of the HSV-2 IgG antibodies according to
age group showed that 9 (42.8%) out of the 21
pregnant women in the 17-20 age group, 20 (54.1%)
out of the 37 women in the 21-25 age group, 28 (70%)
of the 40 pregnant women in the 26-30 age group and
25 (78.1%) of the 32 pregnant women above 30 years
old had HSV-2 IgG (Figure 1).
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September 1999 and May 2001. In order to determine
the seroprevalence of asymptomatic HSV infections in
pregnant women, blood samples for antibody study were
collected from 130 randomly selected pregnant women.
The existence of HSV IgG and IgM antibodies in the serum
samples was tested by ELISA. Blood samples were
centrifuged at 1500 rpm for 5 min to obtain serum
samples.
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Figure 1. The distribution of HSV-2 IgG antibodies according to age.
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Thirty-four percent (39/117) of the 117 pregnant
women with a history of oral herpes had antibodies to
HSV-1 IgG only; 3.4% (4/117) of these women had
antibodies to HSV-2 only, and 59.8% (70/117) had
antibodies to both HSV-1 and HSV-2. Furthermore,
3.4% (4/117) of the pregnant women were seronegative
for HSV (Figure 2).

Examination of the 18 HSV-2 IgM positive pregnant
women by age group showed that 2 (9.5%) out of the 21
of the 17-20 age group, 11 (29.7%) out of 37 in the 2125 age group, 3 (7.5%) out of 40 in the 26-30 age
group and 2 (6.3%) out of 32 in the above 30 age group
had the HSV-2 IgM antibody (Figure 4).
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Figure 4. The distribution of HSV-2 IgM in a total of 18 pregnant
women according to age group.
Figure 2. The antibody distribution of HSV-1 and HSV-2 IgG in a total
of 117 pregnant women with an oral herpes history.

Three (23.1%) of 13 pregnant women without an
oral herpes history had only HSV-1 IgG antibodies, and 7
(53.8%) of these pregnant women had both HSV-1 IgG
and HSV-2 IgG antibodies. One (8%) of them had only
HSV-2 IgG antibody. In addition, 2 (15%) of these 13
pregnant women were seronegative for HSV (Figure 3).
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Figure 3. The antibody distribution of HSV-1 and HSV-2 IgG in a total
of 13 pregnant women without an oral herpes history.

Discussion
HSV infection occurs worldwide but its epidemiology
varies between different countries and between groups of
individuals. The seroprevalence of HSV-1 and HSV-2
antibodies is an accurate method of determining the
epidemiology of this infection (6,7). Even though genital
herpes infection in pregnant women is common and
rarely serious, the risk of vertical transmission to the
infant when the mother develops a primary infection
during the third trimester is high and this risk increases
the closer to the time of delivery (7-12).
The identification of pregnant women with genital
herpes infection is necessary for the protection of babies
from the risk of neonatal herpes. Type-specific HSV
serologic screening has been recommended to identify
women at risk of acquiring genital HSV-1 or HSV-2
infections close to term, a setting in which there is high
risk (30-50%) of neonatal herpes (6-13,14).
In this study, we investigated the incidence of HSV
infections in pregnant women at delivery. While the
prevalence of HSV-2 IgG was 63.1% (82/130) in the
pregnant women, the prevalance of HSV-1 IgG was 90%
(117/130).

99

Serological Evaluation of HSV-1 and HSV-2 Infection in Pregnancy

Among the 117 pregnant women with an oral herpes
history 34% and 3% were found to have antibodies
against HSV-1 and HSV-2, while 60% had antibodies
against both HSV-1 and HSV-2, and 3% were
seronegative (Figure 2).

Eskild et al. (19), in their study on 961 pregnant
women, reported HSV-2 antibodies in 256 (26.6%)
cases, and an increase in prevalence with age (17% in the
20-24 age group and 34% in the above 30 age group
(19)).

Seven (39%) of the 18 pregnant women with HSV-2
IgM positivity had an oral herpes history while 11 (61%)
of these women had no oral herpes history. This seems to
be in line with the view that the presence of HSV-1
antibodies results in a reduction in the development of
HSV-2 infections, no matter how small (10-14).

Avraja et al. (20) reported a prevalence of 16% for
the HSV-2 IgG antibody and 70% for the HSV-1 gG1
antibody among pregnant women in Finland and also
found active HSV-2 and HSV-1 infection during the
course of pregnancy in 5 (0.6%) and 9 (0.9%) of the
women, respectively (20).

HSV-2 seroprevalence increased significantly with age
(p<0.01). Examination of the distribution of the
prevalence of the HSV-2 IgG by age revealed an increase
from 43% in the 17-20 age group to over 78% in the
above 30 age group (Figure 1).

Hashido et al. (21) in their study on pregnant women
in Japon reported the seroprevalence of HSV-2 as 7%.
Due to the downward trend in the incidence of HSV-1
infections during childhood in Japan, primary genital
HSV-2 infections have been estimated to have become
more common (21).

Studies on the prevalence of HSV-2 infection among
pregnant women are limited in Turkey. Arseven et al.
(15) investigated the distributions of anti-HSV-1 and
HSV-2 IgG and IgM antibodies in sera obtained from 296
pregnant women. While 24 (8.11%) of 287 HSV-1 IgG
antibody positive patients were IgM positive, anti-HSV-1
IgM alone was not detected in any patients. In 16
(5.41%) of 125 (42.23%) patients who were positive
for the HSV-2 IgG antibody HSV-2 IgM antibodies were
detected as well. The presence of HSV-2 IgM was found
in only 4 (1.3%) of the pregnant women (15).
Cengiz et al. (16), in their study on 73 mothers with
various obstetric problems like abortion, stillbirth,
premature birth and intrauterine developmental
retardation, reported HSV-1 positivity in 71 (97.3%),
HSV-2 IgG positivity in 65 (89%) and HSV-2 IgM
positivity in 6 (8%) (16).
With regard to studies from other countries on the
seroprevalence of HSV-2 in asymptomatic pregnant
women, Frenkel et al., in the USA in their study on 1355
pregnant women without histories of genital herpes,
detected HSV-2 seropositivity in 439 (32.4%) cases (17).
Enders et al. (18), reported an 8.9% HSV-2 infection
ratio among 1999 pregnant women examined in
Germany. They found that 20.7% of the pregnant
women were seronegative for both HSV-1 and HSV-2 IgG
antibodies, hence the conclusion was that an increased
risk of the development of both types of primary HSV
infection existed (18).
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Dong et al. (22) reported the prevalence of HSV-2 IgG
as 69.1% in 233 pregnant women and that of HSV-2
IgM as 3%. In this group HSV-1 IgG and HSV-1 IgM
antibodies were respectively 66.7% and 2.5% (22).
Carvalho et al. (23) reported a 22.6% HSV-2
seropositivity in Brazil among 102 pregnant women
studied, with only 1 of them having a history of genital
herpes. These data demonstrate that regardless of the
presence or absence of a history of genital herpes viral
spread could be very common (23).
In our study, the 63.1% HSV-2 antibody prevalence
found in the asymptomatic pregnant women approaches
the seroprevalence of HSV-2 reported by Arseven et al.
(15). That reported by Dong et al., however, is similar. In
contrast to this, the prevalence of HSV-2 infection among
pregnant women varies from 7% to 32%. Demographic
criteria and socio-economic factors are possible
determinants of differences in the seropositivity ratios of
HSV-2. The prevalence of HSV-2 infection increases with
advanced age, more sexual partners, early age of first
sexual intercourse, history of sexually transmitted disease
and lower socio-economic status (24,25).
In a study by Eskild et al. (19) from Norway, an
increase in the prevalence of HSV-2 with advancing age
has been reported. In our study group, the observation
that the HSV-2 IgM antibody response was highest in the
21-25 age group among the pregnant women with a
ratio of 30% demonstrates clearly that this age group is
especially at risk of developing primary or reactive genital
HSV-2 infection.
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In conclusion, these results confirm a high prevalence
of HSV infection in Adana. To improve recognition of
genital herpes near term, obstetricians should counsel
pregnant women about the high prevalence and mild and

diverse symptoms of genital HSV-2 infection. In addition,
it is recommended that pregnant women who are
susceptible to primary genital HSV-2 infections should be
identified by HSV-2 IgG 2 type specific serological tests.
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